SCHEMBL2514657

SCHEMBL2514657

CN(C(=O)O)[C@H]1COCc2nc3cnc4ccccc4c3n21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33
JAK1 P23458 7/20 0.32
TSPO P30536 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
JAK2 O60674 5/20 0.31
JAK3 P52333 2/20 0.31
TYK2 P29597 1/20 0.31
ELANE P08246 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.30
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2511886 0.82 TLR7 (0.41)
SCHEMBL2511389 0.80
SCHEMBL2514925 0.79 GRM5 (0.34) ALDH1A1MAPT
SCHEMBL2514656 0.76 ABL1 (0.35) HSD17B10ALDH1A1TP53JAK1JAK2
SCHEMBL1774978 0.76 TLR7 (0.34) HSD17B10ALDH1A1JAK1JAK2JAK3
SCHEMBL1775498 0.76 JAK1 (0.35) JAK1NPC1RAB9AJAK2JAK3
SCHEMBL1774432 0.76 ABL1 (0.37) HSD17B10ALDH1A1JAK1JAK2JAK3
SCHEMBL1776659 0.74 LRRK2 (0.35) JAK1JAK2JAK3KDM4ELRRK2
SCHEMBL1774365 0.73 TLR7 (0.32) HSD17B10ALDH1A1JAK1JAK2JAK3
SCHEMBL2511908 0.73 GRM5 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350034-B2 Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-08 US disclosed
EP-1831221-B1 SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 EP disclosed
US-20110293654-A1 SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMANY 2011-12-01 US disclosed
US-8034938-B2 Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-10-11 US disclosed
US-20080085895-A1 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds 3M INNOVATIVE PROPERTIES COMPANY 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110293654-A1 SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNG, IL4, IFNAR1 HSD17B10 1897/4885ALDH1A1 1204/4885TP53 286/4885
US-20080085895-A1 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNG, IL4, IFNAR1 HSD17B10 1897/4885ALDH1A1 1204/4885TP53 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.